DANIEL G BRUETMAN

Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology CHICAGO, IL NPI 1972583417

General Payments — all program years on this page

$5,798.01

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 81
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $463.93 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $393.9417
Education $69.991

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $3,603.4210
2019 $828.0714
2020 $65.943
2021 $170.8910
2022 $541.8921
2023 $123.875
2024 $463.9318

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086753865 Novartis Pharmaceuticals Corporation $22.48 02/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086753873 Novartis Pharmaceuticals Corporation $34.04 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086753877 Novartis Pharmaceuticals Corporation $1.03 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086753879 Novartis Pharmaceuticals Corporation $30.25 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086753883 Novartis Pharmaceuticals Corporation $2.49 10/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086753885 Novartis Pharmaceuticals Corporation $21.69 10/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086753889 Novartis Pharmaceuticals Corporation $25.76 12/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1089403734 Daiichi Sankyo Inc. $16.48 12/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1091992937 Ipsen Biopharmaceuticals, Inc $69.99 11/06/2024 Education Undisputed 01/23/2026 View at CMS
1104283241 AstraZeneca Pharmaceuticals LP $34.60 09/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105869291 AstraZeneca Pharmaceuticals LP $21.76 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120083072 ACCORD HEALTHCARE, INC. $17.09 10/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132993569 Genentech USA, Inc. $24.84 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133831965 Gilead Sciences, Inc. $24.68 11/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139372353 Astellas Pharma US Inc $23.51 08/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141763755 Merck Sharp & Dohme LLC $34.50 03/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141937859 Merck Sharp & Dohme LLC $28.42 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144954333 Takeda Pharmaceuticals U.S.A., Inc. $30.32 07/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.